Background The purpose of this study was to analyze the detectability of colorectal neoplasia with fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography/ computed tomography (FDG-PET/CT). Methods Data for a total of 492 patients who had undergone both PET/CT and colonoscopy were analyzed. After the findings of PET/CT and colonoscopy were determined independently, the results were compared in each of the six colonic sites examined in all patients. The efficacy of PET/CT was determined using colonoscopic examination as the gold standard. Results In all, 270 colorectal lesions 5 mm or more in size, including 70 pathologically confirmed malignant lesions, were found in 172 patients by colonoscopy. The sensitivity and specificity of PET/CT for detecting any of the colorectal lesions were 36 and 98%, respectively. For detecting lesions 11 mm or larger, the sensitivity was increased to 85%, with the specificity remaining consistent (97%). Moreover, the sensitivity for tumors 21 mm or larger was 96% (48/50). Tumors with malignant or highgrade pathology were likely to be positive with PET/CT. A size of 10 mm or smaller [odds ratio (OR) 44.14, 95% confidence interval (95% CI) 11.44-221.67] and flat morphology (OR 7.78, 95% CI 1.79-36.25) were significant factors that were associated with false-negative cases on PET/CT. Conclusion The sensitivity of PET/CT for detecting colorectal lesions is acceptable, showing size-and pathology-dependence, suggesting, for the most part, that clinically relevant lesions are detectable with PET/CT. However, when considering PET/CT for screening purposes caution must be exercised because there are cases of false-negative results.
Introduction
Fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) is well accepted in the imaging workup of various malignancies. Accordingly, PET has been shown to detect a wide variety of tumor foci including lymphoma, melanoma, lung cancer, and colorectal cancer (CRC). PET is now widely used and has shown high sensitivity in the diagnosis, staging, therapeutic monitoring, and restaging of diverse cancers [1] . Furthermore, combined PET/computed tomography (CT) is superior to PET or CT alone for localizing metabolically active foci and in readily distinguishing physiological activity from pathological findings [2] . However, PET/CT is occasionally faulted for revealing intense metabolic activity at sites not considered to be related to the malignant process under study, as well as for not discovering all clinically relevant neoplastic lesions [3] .
For detecting colorectal neoplasia, colonoscopy has been considered to be the most accurate method. However, colonoscopy is sometimes burdensome for patients because of the requirement for preparation with laxative use, abdominal fullness due to air insufflation, and possible complications occurring, such as perforation. Recently, CT colonography (CTC) has been shown to have sensitivity of up to 65% for lesions of 5 mm or more, and 90% for lesions of 10 mm or more [4] . However, as with colonoscopy, CTC also requires the use of a laxative and air insufflation. Although guaiac or immunochemical fecal occult blood tests are commonly used for CRC screening worldwide, the sensitivity of such tests alone is not satisfactory even if they are performed repeatedly [5] [6] [7] .
The usefulness of PET or PET/CT, which is non-invasive and requires no particular preparation, for the incidental detection of premalignant colonic lesions has been previously reported [8] [9] [10] [11] . In addition, several studies have recently reported the detectability of colorectal neoplasia by PET or PET/CT. However, these studies had problems in precisely evaluating the ability of PET. Principally, these studies were small-scale and/or used a biased cohort [10, 12, 13] , and not all patients underwent both PET and colonoscopy [11, [14] [15] [16] [17] . In addition, no largescale studies have been conducted using PET/CT for detecting colorectal lesions according to morphology, pathology, and location. Therefore, the previous studies could not show unambiguous results regarding the usefulness of PET/CT for detecting colorectal lesions. It remains to be determined whether PET/CT can be used as a modality for the screening of colorectal malignancy and clinically relevant colorectal lesions.
In this study, therefore, we examined the ability of PET/CT to detect colorectal neoplasia in a large cohort, using the findings of colonoscopy as the gold standard. All patients in this cohort had undergone both PET/CT and colonoscopy within an interval of 1 year. In this large cohort, moreover, we determined the sensitivity of PET/CT for detecting colonic neoplasia according to tumor characteristics such as pathology, morphology, and location. In addition, we determined patient and tumor factors contributing to false-negative results with PET/CT, because such cases are problematic in using PET/CT as a screening modality.
Patients and methods

Patients
This was a retrospective study based on chart and image reviews of patients who had undergone both PET/CT and colonoscopy within 1 year. A total of 7,014 patients who were treated at Okayama University Hospital underwent PET/CT at Okayama Diagnostic Imaging Center between April 2006 and January 2010. Of these, 587 patients underwent colonoscopy at Okayama University Hospital in the same year before or after PET/CT. The following patients were excluded from the study: 54 patients who had a history of prior colon resection; 32 patients with incomplete colonoscopy; and 9 patients with a serum glucose level of more than 150 mg/dl measured at 18 F-FDG injection. Thus, data for 492 patients (306 men, 62%; 186 women, 38%) with a median age of 66 years (range 10-88) were analyzed.
Demographic data, medical history including primary cancer, and the indication for PET/CT were obtained from the patients' medical charts. This study was approved by the Institutional Review Board of Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.
PET/CT imaging protocol PET/CT was carried out in the recommended standard condition with a PET/CT Scanner Biograph LSO/Sensation 16 (Siemens, Munich, Germany) at Okayama Diagnostic Imaging Center. All patients fasted for at least 5 h before the PET/CT studies. The serum glucose level measured at the time of 18 F-FDG injection was confirmed to be less than 150 mg/dl in all patients. 18 F-FDG (3.7 MBq/kg body weight) was administered intravenously into the arm and the patient was then seated on a chair to rest for 90 min for uptake, while drinking 350 ml of mineral water for hydration. A whole-body PET/CT scan from the upper end of the orbit to the femoral region was performed 90 min after the 18 F-FDG administration. The patients were in the supine position and their bilateral upper limbs were elevated. The scans consisted of seven to eight bed positions, with 2.4 min per position. Urinary tract activity was minimized in most patients by the placement of a Foley catheter before the injection of 18 F-FDG and by administering furosemide and intravascular fluids after the injection of 18 F-FDG. PET images were scatter corrected and reconstructed using an ordered-subset expectation maximization (OSEM) iterative reconstruction algorithm and with the use of a post-reconstruction Gaussian filter (3 mm full width half maximum). A technical parameter for a 16-detector row helical CT induced a section thickness of 3 mm and was obtained from the base of the skull through the proximal thighs at 140 kV and 12-40 m as for attenuation collection and diagnosis.
Interpretation
All 18 F-FDG PET/CT images were interpreted by two of the authors (T.H. and Y.O.) without knowledge of the results of the colonoscopy. The colon was divided into six segments on the PET/CT images: cecum, ascending colon (including the hepatic flexure), transverse colon, descending colon (including the splenic flexure), sigmoid colon, and rectum. This division was established to accurately localize the 18 F-FDG hotspots, allowing for easier matching with the colonoscopic findings.
Any focal glucose uptake in the colon significantly higher than background was considered abnormal. Physiological 18 F-FDG uptake due to fecal stasis, if present, was distinguished from uptake due to the presence of neoplastic lesions, the former usually being diffuse, and by analyzing the CT images.
Colonoscopy
On the day of the colonoscopy, the patients received colonic lavage with two liters of a polyethylene glycolbased electrolyte solution for bowel preparation, in accordance with the recommended protocol of the manufacturer (Ajinomoto Pharma, Tokyo, Japan). All colonoscopies were performed by an experienced endoscopist who used a colonoscope with magnifying function and narrow band imaging (NBI) (CF-H260AZI, PCF-Q240ZI, EVIS LUCERA; Olympus, Tokyo, Japan). All tumors found at colonoscopy were observed with magnification using dye-spraying and the NBI mode. The tumors were then endoscopically diagnosed as malignant lesions (CRC, lymphoma, or metastatic cancer) or nonmalignant polyps (adenoma or hyperplastic) according to the definitions of Kudo et al. [18] [19] [20] and Katagiri et al. [18] [19] [20] . All tumors that were suspicious for malignancy by magnifying colonoscopy were pathologically examined in specimens collected by biopsy, polypectomy, or surgical resection. CRC was defined as an invasive cancer with involvement of the submucosal layer of the colorectum, and intramucosal carcinoma was defined as a high-grade adenoma. Not all polyps that were regarded as non-malignant were examined pathologically, because a considerable number of patients had more serious disease than colorectal polyps. The endoscopists were blinded to the results of PET/CT if the PET/CT was performed prior to the colonoscopy.
The colonoscopic findings were determined from colonoscopy reports written by the endoscopists. In addition, all endoscopic images recorded in digital media were reviewed and confirmed by two of the authors (J.K. and S.H.), who were blinded to the results of PET/CT. The location of tumors was determined and recorded by dividing the colon into six segments, as was done with PET/CT. The size of the tumors was determined by measuring extirpated specimens when polypectomy or surgical resection was performed. If tumors were not resected, the size was estimated from the endoscopic images. The macroscopic appearance of colorectal lesions was defined as protruded (pedunculated or sessile) or flat. A flat-type colorectal tumor was endoscopically defined by a height of less than half of its diameter, or it was histologically defined by the thickness of the lesion being less than twice that of the adjacent normal colonic mucosa, with or without depressive areas [21, 22] .
Comparison of findings between PET/CT and colonoscopy
After the findings of PET/CT and colonoscopy had been determined independently, the results were compared in each of the six colonic sites examined in all patients. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of PET/CT for detecting colonic lesions were determined relative to the colonoscopic findings as the gold standard. Polyps smaller than 5 mm found at colonoscopy were not included in the analysis, because PET/CT was insensitive to lesions smaller than 5 mm in the large intestine. When two or more polyps were found at any colonic site by colonoscopy, polyps of the greatest dimension were compared against their counterparts detected by PET/CT. In analysis by location, the proximal colon was defined as the cecum, ascending colon, and transverse colon, while the distal colon included the descending colon, sigmoid colon, and rectum. In patients in whom PET/CT was performed after polypectomy during colonoscopy, the resected polyps were not counted.
Statistical analysis
Sensitivity, specificity, PPV, NPV, and accuracy were determined based on comparisons between the PET/CT and colonoscopy findings at six colonic sites in all 492 patients. Ninety-five percent confidence intervals (95% CI) were calculated for these estimates. Univariate analyses were performed with the v 2 test or Fisher's exact test, and multivariate analysis was performed with the logistic regression model. A two-sided P value of less than 0.05 was accepted as significant. Statistical analysis was conducted using JMP 8 software (SAS Institute, Cary, NC, USA).
Results
Patients and colonoscopic findings Diagnostic ability of PET/CT for colorectal lesions Table 2 shows the sensitivity, specificity, PPV, NPV, and accuracy of PET/CT for detecting colorectal lesions. Positivity or negativity for PET/CT was determined at six colonic sites in each patient, and compared with the findings of colonoscopy. Hence, the data obtained were based on 2,952 colonic sites in the 492 patients. The median interval between colonoscopy and PET/CT was 14 days (range 0-364).
The results are shown according to tumor size (5 mm or more: n = 270; 11 mm or more: n = 97; and 21 mm or more: n = 50). The sensitivity and specificity for tumors 5 mm or more were 36 and 98%, respectively. Hence, the sensitivity for tumors that were 5-10 mm in size was only 9.2% (16/173). However, the sensitivity for tumors 11 mm or more was higher, at 85% (82/97). Moreover, the sensitivity for tumors 21 mm or more was 96% (48/50), suggesting that the sensitivity of PET/CT for detecting colorectal lesions is sizedependent, and that a large proportion of clinically relevant polyps (larger than 10 mm) are detectable with PET/CT. The specificity was above 96% for any tumors greater than 5 mm, suggesting that few tumors would be found in the PET/CTnegative regions. Endoscopic findings and PET/CT images of one true-positive case and one false-negative case are shown in Fig. 1 .
Sensitivity of PET/CT for detecting colorectal lesions stratified by pathology
The sensitivity of PET/CT for detecting colorectal lesions, stratified by pathology, is shown in Table 3 . The sensitivity for high-grade adenoma and adenoma with villous component was analyzed for 24 pathologically confirmed cases. Although the sensitivity for benign lesions of 5-10 mm was less than 10%, the sensitivity for malignant lesions of similar size was 33%. For 11-to 20-mm lesions, increased sensitivities were seen for malignant lesions (94%), highgrade or villous component (80%), and other polyps (50%). Although almost all lesions measuring 21 mm or more were detectable with PET/CT regardless of pathology, there were two such lesions that were negative on PET/CT. One was a 25-mm flat-type polyp in the cecum, and the other was a 30-mm invasive cancer in the rectum. In the latter case, continuous physiological 18 F-FDG uptake was observed from the descending colon to the rectum.
Sensitivity of PET/CT for detecting colorectal lesions according to location and macroscopic appearance Next, the sensitivity of PET/CT for detecting colorectal tumors was determined according to tumor location and macroscopic appearance (Table 4 ). In general, PET/CT was less sensitive for tumors in the proximal colon. In particular, the difference in sensitivity between the proximal and distal colon was greater for 11-to 20-mm tumors (53 vs. 81%, respectively). Macroscopically flat lesions were likely to be negative on PET/CT (the sensitivity for 11-20-mm tumors was 44% for flat vs. 79% for protruded lesions), although the number of flat lesions was small compared to that of protruded lesions. These results suggest that the detectability of colorectal lesions by PET/CT is different according to tumor location and/or morphology.
Identification of factors that contributed to false-negative findings on PET/CT Differences were shown in PET/CT sensitivity for detecting colorectal lesions according to tumor characteristics. In clinical practice, false-negative findings on PET/CT studies of clinically relevant lesions would be problematic. We determined the factors that contributed to false-negative 
Discussion
In the present study, we demonstrated the sensitivity of PET/CT for detecting colorectal lesions in a large cohort, of which approximately 500 patients had undergone both PET/CT and colonoscopy. To the best of our knowledge, this is the largest cohort among studies that have examined the performance of PET/CT for colorectal lesions. Besides using this large cohort, we analyzed the sensitivity of PET/CT according to tumor characteristics such as tumor size, pathology, morphology, and location. In particular, in-depth analysis regarding colonic location was performed by calculating the sensitivity for each of six colon sections. This analysis showed that there was a difference in the sensitivity of PET/CT between the proximal and distal colons. Another original and strong facet of this study was the identification of factors contributing to false-negative results on PET/CT. Although PET/CT may have the potential to be used as a screening modality for colorectal neoplasia, data accounting for the pros and cons of the problem are limited. Successful identification of falsenegative factors in the large cohort in this study may clarify the issues on this topic. We demonstrated that the sensitivity of PET/CT for detecting colorectal lesions larger than 10 mm was approximately 85%, which was similar to the results shown in previous studies [13, 23] . Although the size-and pathology-dependence (higher in high-grade and villous component, and malignancy) of PET/CT sensitivity had also been observed in previous reports [9, 12, 13] , our large-scale study provided sufficient data for confirming the efficacy of PET/CT for detecting clinically relevant colorectal lesions. In contrast to previous reports, we calculated the specificity, PPV, NPV, and accuracy by dividing the total colon into six segments. Because the prevalence of colorectal lesions is relatively low, specificity, NPV, and accuracy were likely to be higher, while PPV tended to be lower than the results in the previous reports. In clinical settings, however, the interpretation of PET/CT images is usually made by dividing the colon in the way we did in this study, and hence these values may reflect the true performance of PET/CT for detecting colorectal lesions.
Our results indicated that neoplasia in the proximal colon and flat lesions were likely to be false-negative on PET/CT. In particular, a flat appearance was an independent factor that contributed to being false-negative on PET/CT. Friedland et al. [12] also reported that PET was insensitive for flat lesions. They reported that the sensitivity for flat lesions was 23% in precancerous lesions larger than 10 mm, which was lower than our results (50%, 6/12), possibly because PET alone is less sensitive than PET/CT for colonic lesions [2] . In addition, the difference may be attributed to the fact that almost all (11/13) of the flat lesions they reported were located in the proximal colon, in which PET is likely to be insensitive for polyps. Although the precise reasons for the insensitivity of PET/CT for flat and/or proximal colonic neoplasia are unknown, the following factors may be involved. First, PET sensitivity may be affected by tumor volume. Because PET reflects the metabolic activity of a tumor, its sensitivity depends on tumor volume, i.e., the number of tumor cells [24] . Flat lesions generally have smaller volumes and consist of smaller numbers of tumor cells than protruded lesions. Therefore, PET/CT would be insensitive for these flat lesions. Second, flat lesions are likely to be located in the proximal colon, and the tumor cells in proximal neoplasia may have different glucose metabolism from the cells in the distal colon. Biological differences have been shown between proximal and distal colon cancers: proximal cancers are likely to be microsatellite-unstable, hypermethylated, p53-wild, and diploid, while distal cancers tend to be chromosomal-unstable, lower methylated, p53-mutated, and aneuploid [25] [26] [27] . Therefore, differences in glucose metabolism may exist between proximal and distal neoplasias. A recent proteome analysis showed that glucose was lower in microsatellite instability-high colorectal tumors than in microsatellite-stable tumors [28] . In the future, we may be able to evaluate molecular differences in colorectal tumors according to PET/CT positivity. Moreover, it has been reported that the growth rate of adenomas in the proximal colon is lower than that of adenomas in the distal colon [29] . A lower growth rate is probably correlated with a lower rate of cell division, which involves poor glucose metabolism, resulting in poor PET/CT sensitivity.
We have shown that PET/CT has reasonable sensitivity for clinically significant colorectal neoplasia. An emerging issue is the possibility of using PET/CT in screening for colorectal neoplasia. Minamimoto et al. [30] reported that the sensitivity of PET and PET/CT for CRC in an asymptomatic population was 90%, on the basis of more than 50,000 cases analyzed in a Japanese Nationwide Survey. Our results were comparable to these findings, though admittedly the data were on a lesser scale. The main goal of CRC screening is the detection of advanced neoplasia, and the sensitivity of PET/CT for these lesions was 75% in our study. This percentage is marginally lower than the sensitivity of CTC, which is a similar non-invasive radiology-based method. Previous studies indicated that the sensitivity of CTC for advanced colorectal neoplasia was 86-90%, and this method was recommended as one of the screening options for CRC by the American Gastroenterological Association [4, 31, 32] . PET/CT, however, has the advantages of not requiring bowel preparation and of detecting cancers in other organs. These advantages may facilitate the use of PET/CT as a preferable screening test for cancers in the whole body, including CRC. Although PET/CT is a non-invasive method, exposure to radiation, which may cause cancer development or affect other health conditions, is a serious problem. Hence, PET/CT is impractical for annual or biannual screening purposes. Determining the optimal interval for CRC screening with PET/CT is a further problem, considering the questions of its effectiveness and safety.
In Japan, one session of whole-body PET/CT is provided for approximately $1,000, which is higher than the cost of a colonoscopy, and much higher than the cost of a fecal occult blood test. Thus, PET/CT is a very expensive procedure for the detection of only colorectal neoplasia, regardless of its relatively high sensitivity and safety. At the same time, the cost of using PET/CT to detect malignancies in other organs, as well as in the colorectum, needs to be evaluated. Ultimately, PET/CT for screening use will be subjected to a cost-effectiveness analysis.
Our data concurred with previous studies in that colonoscopy should be performed in patients with positive results on PET/CT. However, for screening purposes, negative results on PET/CT do not justify dispensing with colonoscopies, regardless of false-negative findings. Our results indicated that, in particular, small but relevant lesions and flat lesions were likely to be missed by PET/CT. Although PET/CT could be used in whole-body cancer screening, it should be noted that it is not perfect, at least for CRC. Clinicians should inform patients receiving PET/CT screening of this limitation. For screening, PET/CT may be more practical when used in combination with a more noninvasive test such as a fecal occult blood test.
It should also be noted that our results do not apply to inflammatory bowel disease (IBD)-related malignancy, because FDG can be incorporated in the intestine with inflammation. In fact, there have been reports regarding the feasibility of evaluating the inflammatory status of IBD with PET/CT [33] . In addition, a large proportion of dysplasias/cancers observed in ulcerative colitis are flat lesions, which are likely to escape detection with PET/CT. The detection of IBD-related malignancies with PET/CT remains as an important problem, because no other modalities can definitively detect these lesions.
The limitations of the present study include those inherent in any retrospective analysis of a single institution's experience. Secondly, some of the locations detected by PET/CT may have been inaccurate, because colonic location was determined with PET positivity by analyzing recorded CT images. However, coronal and sagittal section images of CT were used concurrently. Therefore, any inaccuracy of localization was considered minimal. Third, not all polyps that were regarded as non-malignant were examined pathologically, because a considerable number of patients had more serious disease than colorectal polyps. Therefore, the category 'other polyps' in Table 3 may have included some high-grade or villous adenomas, resulting in overestimation of PET/CT sensitivity for insignificant lesions. Fourth, most of the patients in this study harbored a malignancy as an underlying disease, and this factor precluded an accurate estimate of the utility of PET/CT as a screening tool for colorectal neoplasia in an asymptomatic population. In our study, 12% of the patients analyzed had colorectal malignancies, and 28% had colorectal polyps. The high prevalence of target lesions could make our data on sensitivities and specificities different from those for an asymptomatic population. Fifth, we analyzed patients who had undergone both PET/CT and colonoscopy within a maximum interval of 1 year, which may be considered a wide range. However, because the actual median interval was 14 days, comparison of the results between the two methodologies was considered reasonable. Finally, although we used colonoscopy findings as the gold standard, nevertheless, colonoscopy has been shown to be imperfect and it can miss relevant polyps [34] .
In conclusion, our study found that most clinically important colorectal lesions were detectable with PET/CT. However, it should be noted that PET/CT was less sensitive for detecting smaller lesions and flat and/or proximal lesions. The interpretation of PET/CT whole-body studies should be performed, considering our findings in the detection of colonic neoplasia. For PET/CT use in CRC screening settings, there are still problems to be investigated, including radiation exposure, appropriate screening intervals, and the existence of false-negative cases.
